









Markets
/
Stocks
/
nasdaq-anik
/

Anika Therapeutics Inc

ANIK

10.460USD

+0.160+1.55%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

150.84MMarket Cap

LossP/E TTM



Anika Therapeutics Inc

10.460

+0.160+1.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Anika Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Anika Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 9 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 16.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anika Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

9 / 205

Overall Ranking

76 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Anika Therapeutics Inc Highlights

StrengthsRisks

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 119.91M.

Fairly Valued

The company’s latest PE is -4.61, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.37M shares, decreasing 0.01% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 533.02K shares of this stock.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

16.000

Target Price

+49.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Anika Therapeutics Inc is 6.98, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 27.82M, representing a year-over-year decrease of 28.22%, while its net profit experienced a year-over-year decrease of 92.22%.

Score

Industry at a Glance

Previous score

6.98

Change



Financials

9.80

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.28

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Anika Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Anika Therapeutics Inc is 8.80, ranking 5 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -4.61, which is -57.48% below the recent high of -1.96 and -582.91% above the recent low of -31.46.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Anika Therapeutics Inc is 9.00, ranking 6 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 16.00, with a high of 16.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

16.000

Target Price

+49.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Anika Therapeutics Inc

ANIK

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Anika Therapeutics Inc is 8.48, ranking 32 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 11.27 and the support level at 9.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.14

Change

1.34

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.285

Buy

RSI(14)

66.629

Neutral

STOCH(KDJ)(9,3,3)

73.817

Neutral

ATR(14)

0.358

Low Volatility

CCI(14)

129.027

Buy

Williams %R

25.259

Buy

TRIX(12,20)

0.131

Sell

StochRSI(14)

53.234

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.216

Buy

MA10

9.697

Buy

MA20

9.576

Buy

MA50

9.575

Buy

MA100

9.516

Buy

MA200

10.177

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Anika Therapeutics Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 97.19%, representing a quarter-over-quarter decrease of 3.12%. The largest institutional shareholder is The Vanguard, holding a total of 779.16K shares, representing 5.40% of shares outstanding, with 0.33% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Caligan Partners, LP

1.44M

BlackRock Institutional Trust Company, N.A.

920.60K

-1.78%

The Vanguard Group, Inc.

Star Investors

780.66K

+0.15%

BlackRock Financial Management, Inc.

776.43K

+42.17%

Acadian Asset Management LLC

632.79K

+9.93%

Dimensional Fund Advisors, L.P.

601.16K

-3.52%

Boothbay Fund Management, LLC

539.64K

+1.91%

Renaissance Technologies LLC

Star Investors

533.02K

+1.10%

The Capital Management Corporation

551.25K

+34.83%

Geode Capital Management, L.L.C.

335.68K

+4.50%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Anika Therapeutics Inc is 6.04, ranking 67 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.41. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Anika Therapeutics Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.